| 臺大學術典藏 |
2022-04-14T23:27:49Z |
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
|
Tan, Ryan Shea Ying Cong; Ong, Whee Sze; Lee, Kyung Hun; Lim, Abner Herbert; Park, Seri; Park, Yeon Hee; CHING-HUNG LIN; YEN-SHEN LU; Ono, Makiko; Ueno, Takayuki; Naito, Yoichi; Onishi, Tatsuya; Lim, Geok Hoon; Tan, Su Ming; Lee, Han Byoel; Ryu, Han Suk; Han, Wonshik; Tan, Veronique Kiak Mien; Wong, Fuh Yong; Im, Seock Ah; Tan, Puay Hoon; Chan, Jason Yongsheng; Yap, Yoon Sim |
| 臺大學術典藏 |
2022-03-22T15:05:34Z |
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
|
YEN-SHEN LU; Im, Seock Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Cardoso, Fatima; Harbeck, Nadia; Hurvitz, Sara; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; De Laurentiis, Michelino; Im, Young Hyuck; Kuemmel, Sherko; El-Saghir, Nagi; O'Regan, Ruth; Gasch, Claudia; Solovieff, Nadia; Wang, Craig; Wang, Yongyu; Chakravartty, Arunava; Ji, Yan; Tripathy, Debu |
| 臺大學術典藏 |
2022-03-14T23:45:40Z |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
PO-HAN LIN; Chen, Shin Cheh; Tseng, Ling Ming; Chang, King Jen; Huang, Ai Chu; Cheng, Kuo Chih; Yang, Karen; Wu, Hui Chen; Chao, Tsu Yi; Chang, Yuan Ching; Lin, Peng Chan; WEN-HUNG KUO; Kuo, Wen Lin; CHING-HUNG LIN; Chen, Huo Mu; Yeh, Dah Cherng; Liu, Liang Chih; Liu, Chun Yu; Wang, Ming Yang; Lo, Chiao; YEN-SHEN LU; CHIUN-SHENG HUANG |
| 臺大學術典藏 |
2022-03-10T06:15:01Z |
Genomic profiling of premenopausal HR+ and HER2�V metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine therapy and ribociclib
|
Bardia A.; Su F.; Solovieff N.; Im S.-A.; Sohn J.; Lee K.S.; Campos-Gomez S.; Jung K.H.; Colleoni M.; V?zquez R.V.; Franke F.; Hurvitz S.; Harbeck N.; Chow L.; Taran T.; Lorenc K.R.; Babbar N.; Tripathy D.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:15:01Z |
Role of alpelisib in the treatment of pik3ca-mutated breast cancer: Patient selection and clinical perspectives
|
Chang D.-Y.; Ma W.-L.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs
|
Hata T.; Nakamura K.; Yonemori K.; Noguchi E.; Watanabe M.; Sohn J.; YEN-SHEN LU; Yap Y.-S.; Tamura K.; Fujiwara Y. |
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components
|
Lien H.-C.; Lee Y.-H.; Chen I.-C.; Lin C.-H.; Chen T.W.-W.; Lu Y.-T.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2? advanced breast cancer
|
Fasching P.A.; Delea T.E.; YEN-SHEN LU; De Boer R.; Hurvitz S.A.; Moynahan A.; Chandiwana D.; Lanoue B.; Hu H.; Thuerigen A.; O��shaughnessy J. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
|
YEN-SHEN LU; Yeo W.; Yap Y.-S.; Park Y.H.; Tamura K.; Li H.; Cheng R. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
|
YEN-SHEN LU; Wong A.; Kim H.-J. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen I.-C.; Hu F.-C.; Lin C.-H.; Huang S.-M.; Chang D.-Y.; Cheng A.-L.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:14:58Z |
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia
|
Lin C.-H.; Huang R.Y.-J.; Lu T.-P.; Kuo K.-T.; Lo K.-Y.; Chen C.-H.; Chen I.-C.; YEN-SHEN LU; Chuang E.Y.; Thiery J.P.; Huang C.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-12-21T23:17:41Z |
Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2− advanced breast cancer
|
Fasching, Peter A.; Delea, Thomas E.; YEN-SHEN LU; De Boer, Richard; Hurvitz, Sara A.; Moynahan, Aaron; Chandiwana, David; Lanoue, Brad; Hu, Huilin; Thuerigen, Astrid; O’shaughnessy, Joyce |
| 臺大學術典藏 |
2021-11-21T23:19:52Z |
Genomic profiling of premenopausal HR+ and HER2– metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine therapy and ribociclib
|
Bardia, Aditya; Su, Fei; Solovieff, Nadia; Im, Seock Ah; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Jung, Kyung Hae; Colleoni, Marco; Vázquez, Rafael Villanueva; Franke, Fabio; Hurvitz, Sara; Harbeck, Nadia; Chow, Louis; Taran, Tetiana; Lorenc, Karen Rodriguez; Babbar, Naveen; Tripathy, Debu; YEN-SHEN LU |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
|
YEN-SHEN LU; Wong, Andrea; Kim, Hee Jeong |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
|
YEN-SHEN LU; Yeo, Winnie; Yap, Yoon Sim; Park, Yeon Hee; Tamura, Kenji; Li, Huiping; Cheng, Rebecca |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai, Ming Shen; Feng, Yin Hsun; Chen, Shang Wen; Masuda, Norikazu; Yau, Thomas; Chen, Shou Tung; YEN-SHEN LU; Yap, Yoon Sim; Ang, Peter C.S.; Chu, Sung Chao; Kwong, Ava; Lee, Keun Seok; Ow, Samuel; Kim, Sung Bae; Lin, Johnson; Chung, Hyun Cheol; Ngan, Roger; Kok, Victor C.; Rau, Kun Ming; Sangai, Takafumi; Ng, Ting Ying; Tseng, Ling Ming; Bryce, Richard; Bebchuk, Judith; Chen, Mei Chieh; Hou, Ming Feng |
| 臺大學術典藏 |
2021-09-14T23:19:03Z |
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia
|
CHING-HUNG LIN; RUBY YUN-JU HUANG; TZU-PIN LU; KUAN-TING KUO; Lo, Ko Yun; Chen, Ching Hsuan; Chen, I. Chun; YEN-SHEN LU; Chuang, Eric Y.; Thiery, Jean Paul; CHIUN-SHENG HUANG; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-15T00:08:34Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen, I. Chun; Hu, Fu Chang; CHING-HUNG LIN; Huang, Shu Min; Chang, Dwan Ying; ANN-LII CHENG; YEN-SHEN LU |
| 臺大學術典藏 |
2021-04-21T23:30:44Z |
Role of alpelisib in the treatment of pik3ca-mutated breast cancer: Patient selection and clinical perspectives
|
Chang, Dwan Ying; Ma, Wei Li; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-21T23:14:58Z |
Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs
|
Hata, Tomomi; Nakamura, Kenichi; Yonemori, Kan; Noguchi, Emi; Watanabe, Makiko; Sohn, Joohyuk; YEN-SHEN LU; Yap, Yoon Sim; Tamura, Kenji; Fujiwara, Yasuhiro |
| 臺大學術典藏 |
2021-03-10T02:36:33Z |
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
|
Harbeck N.;Franke F.;Villanueva-Vazquez R.;Yen-Shen Lu;Tripathy D.;Chow L.;Babu G.K.;Im Y.-H.;Chandiwana D.;Gaur A.;Lanoue B.;Rodriguez-Lorenc K.;Bardia A.; Harbeck N.; Franke F.; Villanueva-Vazquez R.; YEN-SHEN LU; Tripathy D.; Chow L.; Babu G.K.; Im Y.-H.; Chandiwana D.; Gaur A.; Lanoue B.; Rodriguez-Lorenc K.; Bardia A. |
| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival
|
Chen T.W.-W.;Jan I.-S.;Chang D.-Y.;Lin C.-H.;Chen I.-C.;Chen H.-M.;Cheng A.-L.;Yen-Shen Lu; Chen T.W.-W.; Jan I.-S.; Chang D.-Y.; Lin C.-H.; Chen I.-C.; Chen H.-M.; Cheng A.-L.; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components
|
Lien H.-C.; Lee Y.-H.; Chen I.-C.; Lin C.-H.; Chen T.W.-W.; Lu Y.-T.; YEN-SHEN LU |
